Butaject label

Butaject

Butaject Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

For relief of inflammatory conditions associated with the musculoskeletal system in horses.

Intravenous dosage (not subcutaneous or intramuscular use):

Horses: 1 to 2 g per 1,000 lb body weight (5 to 10 mL/1,000 lb) daily.

Not for use in Horses intended for food.

See package outsert for additional information.

Each mL contains:
Phenylbutazone ……………………….. 200 mg
Benzyl Alcohol Preservative ………10.45 mg
Sodium hydroxide to adjust pH to 9.5 to 10.0
Water For Injection ………………………….q.s.

Store in a refrigerator between 2oC and 8oC (36oF and 46oF).

TAKE TIME OBSERVE LABEL DIRECTIONS

History

There is currently no drug history available for this drug.

Other Information

DESCRIPTION: Phenylbutazone 20% Injection (phenylbutazone) is a synthetic, nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound’s anti-inflammatory properties.  Chemically, phenylbutazone is 4-butyl-1,2-diphenyl-3,5-pyrazolidinedione. It is a pyrazolon derivative entirely unrelated to the steroid hormones, and has the following structural formula:

Formula label

Butaject Manufacturers

  • Butler Animal Health Supply
    Butaject | Butler Animal Health Supply
    No Recall

    Butaject | Butler Animal Health Supply

    Butaject | Butler Animal Health Supply

    HORSES
    INTRAVENOUSLY: 1 to 2 g per 1,000 lbs of body weight (5 to 10 mL/1,000 lbs) daily. Injection should be given slowly and with care. Limit intravenous administration to a maximum of 5 successive days, which may be followed by oral phenylbutazone dosage forms.

    GUIDELINES TO SUCCESSFUL THERAPY
    1.  Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response.
    2.  Response to phenylbutazone therapy is prompt, usually occurring within 24 hours. If no significant clinical response is evident after 5 days, reevaluate diagnosis and therapeutic approach.
    3.  In animals, phenylbutazone is largely metabolized in 8 hours. It is recommended that a third of the daily dose be administered at 8 hour intervals. Reduce dosage as symptoms regress. In some cases, treatment may be given only when symptoms appear with no need for continuous medication. If long-term therapy is planned, oral administration is suggested.
    4.  Many chronic conditions will respond to phenylbutazone therapy, but discontinuance of treatment may result in recurrence of symptoms.